Matches in Wikidata for { <http://www.wikidata.org/entity/Q94140286> ?p ?o ?g. }
Showing items 1 to 47 of
47
with 100 items per page.
- Q94140286 description "im Oktober 2019 veröffentlichter wissenschaftlicher Artikel" @default.
- Q94140286 description "wetenschappelijk artikel" @default.
- Q94140286 description "наукова стаття, опублікована в жовтні 2019" @default.
- Q94140286 name "2227. Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane–Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPECT-NP)" @default.
- Q94140286 name "2227. Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane–Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPECT-NP)" @default.
- Q94140286 type Item @default.
- Q94140286 label "2227. Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane–Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPECT-NP)" @default.
- Q94140286 label "2227. Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane–Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPECT-NP)" @default.
- Q94140286 prefLabel "2227. Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane–Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPECT-NP)" @default.
- Q94140286 prefLabel "2227. Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane–Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPECT-NP)" @default.
- Q94140286 P1433 Q94140286-CF0B7995-024C-4C69-9208-F36184A59313 @default.
- Q94140286 P1476 Q94140286-22D3356F-1912-4331-8DC5-679C96383FD7 @default.
- Q94140286 P2093 Q94140286-0EBDC25B-4BAF-46BE-99A7-55F162532C72 @default.
- Q94140286 P2093 Q94140286-7D62DB9B-9D98-47CF-85CE-E0C16AD06ED3 @default.
- Q94140286 P2093 Q94140286-850A2050-E29C-478C-9AF5-59ECA5DBB502 @default.
- Q94140286 P2093 Q94140286-A03AD111-2CD0-4EE3-B3E1-6249B22BECD5 @default.
- Q94140286 P2093 Q94140286-A57CD155-80BE-442B-8F0C-0F321F007A21 @default.
- Q94140286 P2093 Q94140286-CFF8D530-2826-4874-BE0F-2CD7CEAD810D @default.
- Q94140286 P275 Q94140286-057a9048-13b5-48f9-8f75-981393a29e1d @default.
- Q94140286 P304 Q94140286-36A10948-0DE8-4072-974A-BC46FE633F9E @default.
- Q94140286 P31 Q94140286-8B687E4E-984C-4BDD-97C6-C17B9A60E0F6 @default.
- Q94140286 P356 Q94140286-E780DB10-E8FD-4977-9E08-8FBD03E42A18 @default.
- Q94140286 P433 Q94140286-C7A4CD7D-9031-48FB-9F38-5B4A39F190AD @default.
- Q94140286 P478 Q94140286-24B329F3-7315-4FA2-901C-EFFEC3CCCE00 @default.
- Q94140286 P577 Q94140286-46112236-7E00-4AC7-8760-F16F5D980ABF @default.
- Q94140286 P6216 Q94140286-3bf050bb-fe1d-4a2b-90f8-e0b7de1c7916 @default.
- Q94140286 P921 Q94140286-ACBD4C46-5A4A-43F0-B3D5-CFC35EF7D08D @default.
- Q94140286 P932 Q94140286-54899E83-D09F-42CF-B0CF-AD768B9C6577 @default.
- Q94140286 P356 OFZ360.1905 @default.
- Q94140286 P1433 Q27725953 @default.
- Q94140286 P1476 "2227. Outcomes in Patients with Renal Impairment from a Phase 3 Clinical Trial for Ceftolozane–Tazobactam (C/T) Treatment of Nosocomial Pneumonia (ASPECT-NP)" @default.
- Q94140286 P2093 "Brian Yu" @default.
- Q94140286 P2093 "Christopher Bruno" @default.
- Q94140286 P2093 "Elizabeth G Rhee" @default.
- Q94140286 P2093 "Erin Jensen" @default.
- Q94140286 P2093 "Jennifer A Huntington" @default.
- Q94140286 P2093 "Linping Li" @default.
- Q94140286 P275 Q24082749 @default.
- Q94140286 P304 "S760-S761" @default.
- Q94140286 P31 Q13442814 @default.
- Q94140286 P356 "10.1093/OFID/OFZ360.1905" @default.
- Q94140286 P433 "Suppl 2" @default.
- Q94140286 P478 "6" @default.
- Q94140286 P577 "2019-10-23T00:00:00Z" @default.
- Q94140286 P6216 Q50423863 @default.
- Q94140286 P921 Q42824827 @default.
- Q94140286 P932 "6810491" @default.